Sangamo BioSciences Inc. Sets New 1-Year High at $19.12 (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) set a new 52-week high during trading hours on Thursday, AnalystRatingsNetwork reports. The company traded as high as $19.12 and last traded at $18.37, with a volume of 8,869,251 shares. The stock had previously closed at $13.65.
A number of research firms have recently commented on SGMO. Analysts at Wedbush raised their price target on shares of Sangamo BioSciences to $22.00 in a research note to investors on Thursday. Finally, analysts at Lazard Capital Markets raised their price target on shares of Sangamo BioSciences from $16.00 to $20.00 in a research note to investors on Wednesday, October 23rd. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.75.
In other Sangamo BioSciences news, VP Philip Gregory sold 15,000 shares of Sangamo BioSciences stock on the open market in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.56, for a total transaction of $203,400.00. Following the completion of the transaction, the vice president now directly owns 109,347 shares in the company, valued at approximately $1,482,745. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Sangamo BioSciences has a 52 week low of $6.75 and a 52 week high of $14.60. The stock’s 50-day moving average is $12.71 and its 200-day moving average is $10.70. The company’s market cap is $1.133 billion.
Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, October 23rd. The company reported ($0.11) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.11). The company had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.52 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. The company’s quarterly revenue was up 16.3% on a year-over-year basis. On average, analysts predict that Sangamo BioSciences will post $-0.44 earnings per share for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.